曲妥珠单抗对人表皮生长因子受体-2阳性乳腺癌患者的心血管毒性研究进展  

Research progress on cardiovascular toxicity of trastuzumab in patients with human epidermal growth factor receptor-2 positive breast cancer

作　　者：杨金伟 马楠楠 屈重阳 杜梦楠 张莹[1,2] YANG Jinwei;MA Nannan;QU Chongyang;DU Mengnan;ZHANG Ying(The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300381,China;National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300381,China)

机构地区：[1]天津中医药大学第一附属医院,天津300381 [2]国家中医针灸临床医学研究中心,天津300381

出　　处：《新乡医学院学报》2022年第4期396-400,F0003,共6页Journal of Xinxiang Medical University

基　　金：天津市科委慢病防治重大专项(编号:17ZXMFSY00190);天津市卫生和计划生育委员会中医中西医结合科研课题(编号:2017003)。

摘　　要：曲妥珠单抗作为人表皮生长因子受体-2(HER-2)的特异性拮抗剂,可延长HER-2阳性乳腺癌患者的生存期,目前已成为HER-2阳性乳腺癌患者治疗的基础选择药物。曲妥珠单抗总体安全性较好,但临床中引起的心血管毒性事件也不容忽视。本文综述了曲妥珠单抗在HER-2阳性乳腺癌患者治疗中所致心血管毒性的临床表现、发生率、发生机制、高危因素、监测及防治,以期为临床安全用药提供参考。Trastuzumab,as a specific antagonist of human epidermal growth factor receptor-2(HER-2),can prolong the survival of patients with HER-2 positive breast cancer.Trastuzumab has now become the basic drug of choice for the treatment of patients with HER-2 positive breast cancer.The overall safety of trastuzumab is good,but the clinical cardiovascular toxicity events cannot be ignored.This article reviews the clinical manifestations,incidence,mechanism,high-risk factors,monitoring and prevention of trastuzumab-induced cardiovascular toxicity in patients with HER-2 positive breast cancer,in order to provide a reference for clinical safe drug use.

关 键 词：曲妥珠单抗 乳腺癌 心血管毒性 人表皮生长因子受体-2 

分 类 号：R737.9[医药卫生—肿瘤]